Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies
- Gautam Borthakur
- , Yesid Alvarado
- , Farhad Ravandi-Kashani
- , Jorge Cortes
- , Zeev Estrov
- , Stefan Faderl
- , Percy Ivy
- , Carlos Bueso-Ramos
- , B. Nebiyou Bekele
- , Francis Giles
- The University of Texas Health Science Center at Houston
- National Cancer Institute (NCI)
- University of Texas Health Science Center at San Antonio
Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review
9
Citations
(Scopus)